Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Scan for outdated or missing drivers - takes under a minute3Repair Windows errors before they cause bigger problemsiTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
A 2010 study identified promyelocytic leukemia protein (PML) as a direct molecular target of arsenic trioxide in the acute promyelocytic leukemia (APL) mechanism it examined. The study described how arsenic binding can set off changes that lead to degradation of PML and the leukemia-associated PML-RARα fusion protein. This is a specific finding about APL biology, not evidence that arsenic treats cancer generally.
What target did the study identify?
Zhang and colleagues reported that arsenic trioxide (As2O3) binds directly to PML and PML-RARα, the fusion protein associated with APL. Their study focused on a molecular process involving that fusion protein, rather than on arsenic as a broad anticancer treatment. Zhang et al., 2010
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Candy Medication | $15.95 | Buy on Amazon |
How does arsenic binding lead to protein degradation?
The study describes a sequence of molecular events: arsenic binds cysteine residues in zinc-finger regions of PML or PML-RARα; this encourages PML molecules to join into larger assemblies; those assemblies interact more with UBC9, an enzyme involved in SUMO modification; and increased SUMOylation promotes degradation of the protein.
The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →- Binding: Arsenic attaches to cysteine residues in zinc-finger regions.
- Oligomerization: Binding encourages PML molecules to associate with one another.
- More UBC9 interaction: The resulting assemblies show increased interaction with UBC9.
- SUMOylation and degradation: SUMO modification increases, promoting breakdown of the protein.
In this proposed chain, degradation reduces the PML-RARα fusion protein associated with APL. It explains a mechanism studied in the paper; it is not a complete account of every clinical effect of arsenic trioxide. Zhang et al., 2010
#1 Best Overall
What did contemporary commentary say remained unclear?
In a report published on April 8, 2010, Chemistry World quoted University of Dundee researcher Ron Hay, who had studied SUMO’s role in arsenic-induced PML degradation. Hay said the observations suggested arsenic could act directly on PML-RAR and trigger its destruction by enhancing SUMO modification. He also said it remained unclear how arsenic could substitute for zinc already bound to PML and how that substitution increased SUMO modification. These were comments made in 2010, not a statement of what the field considers unresolved today. Chemistry World, April 8, 2010
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What this finding does—and does not—show
The result is a mechanistic explanation tied to PML-RARα in APL. It does not establish that arsenic trioxide treats other cancers, provide current treatment recommendations, or support using arsenic outside prescribed medical care. The study’s molecular account should not be taken as dosing, safety, or treatment guidance.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →
